2-ADAMANTYLALKYLAMINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION

摘要

The use of a compound of formula (1) wherein X is oxygen or (CR11R12)n; n is 0 or 1; R1, R2, R3, R4, R5, R6, R7, R8, R11 and R12 are independently selected from hydrogen, alkyl, aryl and non-aromatic heterocyclic groups, or each of one or more pair(s) thereof may together form a 3, 4, 5, 6, 7 or 8-membered ring containing 0, 1 or 2 heteroatom(s); R9 is selected from alkyl, aryl and non-aromatic heterocyclic groups; and R10 is selected from hydrogen, halogen, alkyl, aryl and non-aromatic heterocyclic groups; and pharmaceutically acceptable salts and prodrugs thereof, in therapy and the manufacture of amedicament for use in the treatment of a condition generally associated with abnormalities in glutamatergic transmission, particularly Alzheimer's disease, ischaemic stroke, haemorrhagic stroke, epilepsy, multiple sclerosis, pain, drug-induced optic neuritis, myelopathy, glaucoma, peripheral neuropathy, ischaemic retinopathy, traumatic brain or spinal injury, Parkinson's Disease and Huntington's Disease; and novel compounds of formula (1) per se.